)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AEON Biopharma
AEON Biopharma (AEON) investor relations material
AEON Biopharma Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary26 Oct, 2026
Executive summary
Special meeting scheduled for Dec. 15, 2026; the Board recommends FOR all four proposals, with three substantive items and one procedural adjournment vote.
Proposals are independent; reverse-split authority would expire immediately before the first anniversary of approval and does not require implementation.
Voting matters and shareholder proposals
Proposal 1 seeks authority for one 1-for-2 to 1-for-100 reverse split, with the Board selecting the ratio and retaining discretion to abandon it.
Proposals 2 and 3 would include shares underlying pre-funded warrants in the Plan and ESPP evergreen denominators, respectively; other warrants remain excluded.
Proposal 4 would allow one or more adjournments to solicit additional proxies if any substantive proposal lacks sufficient votes.
Each proposal requires FOR votes to exceed AGAINST votes among votes cast; abstentions have no effect, and brokers may vote uninstructed shares only on the routine reverse-split proposal.
Board of directors and corporate governance
Compensation Committee supported the limited Plan and ESPP amendments on Oct. 5, 2026; the Board approved the proposals and called the special meeting on Oct. 7.
No directors are up for election at this meeting; the Board recommends FOR each proposal.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AEON Biopharma
- ABP-450 targets full-label biosimilarity to challenge BOTOX®’s therapeutic dominance.AEON
Corporate presentation - Reverse-split authority and warrant-linked evergreen increases headline the four proposals.AEONProxy filing
- ABP-450 aims to be the first full-label BOTOX® biosimilar, unlocking broad market adoption.AEONCorporate presentation
- Q2 2026 net loss narrowed to $1.2M, but cash burn and dilution risks persist.AEONQ2 2026
- Registration amended for higher-priced Class A shares and warrants, with updated underwriter details.AEONRegistration filing
- Raises $11M via equity and warrants to fund biosimilar development, but faces major financial risk.AEONRegistration filing
- ABP-450 aims to disrupt BOTOX®'s dominance with full-label biosimilarity and broad market access.AEONCorporate presentation
- Q1 2026 net loss was $11.8M; positive FDA feedback and debt reduction support future plans.AEONQ1 2026
- Vote on director elections and auditor ratification at the June 2026 annual meeting.AEONProxy filing
Next AEON Biopharma earnings date
Q3 202613 Nov, 2026
AEON Biopharma
Next AEON Biopharma earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AEON Biopharma Inc. is a biopharmaceutical company focused on the development of therapeutic applications for botulinum toxin. The company aims to advance treatments for a range of medical conditions, particularly in neurology and related therapeutic areas. AEON Biopharma is engaged in clinical research and regulatory processes to expand the use of botulinum toxin beyond aesthetic applications. The company is headquartered in Irvine, California, and its shares are listed on the NYSE.